Condensed Consolidated Statements of Operations (unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Income Statement [Abstract]
Net sales
Cost of sales
Gross profit
Operating expenses:
Research and development, net of grants	645	334
Clinical and regulatory, net of grants	105	37
General and administrative	1,466	2,472
Total operating expenses	2,216	2,843
Loss from operations	(2,216)	(2,843)
Interest income	4
Net loss	$ (2,212)	$ (2,843)
Net loss per common share – basic and diluted	$ (0.06)	$ (0.12)
Weighted average common shares outstanding – basic and diluted	39,409	23,537